Newsfeed | Navigating EGFR

Did Vera’s Earlier Phase 3 eGFR Alignment With FDA Just Shift Vera Therapeutics' (VERA) Investment Narrative?

Read more about Did Vera’s Earlier Phase 3 eGFR Alignment With FDA Just Shift Vera Therapeutics' (VERA) Investment Narrative?

Vera Therapeutics recently announced it had reached alignment with the U.S. FDA on an earlier Phase 3 ORIGIN eGFR analysis plan to support potential full approval of atacicept for adults with IgA nephropathy, with a PDUFA date set for July...

Vera Therapeutics announces alignment with FDA on earlier ORIGIN 3 eGFR analysis

Read more about Vera Therapeutics announces alignment with FDA on earlier ORIGIN 3 eGFR analysis

Vera Therapeutics (VERA) announced it has aligned with the U.S. Food and Drug Administration on a revised, earlier ORIGIN 3 eGFR analysis plan to support full approval for atacicept in adults with IgAN. “The eGFR results are now expected in...

Lantern Pharma Reports HARMONIC(TM) Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer; Exon 21 L858R NSCLC...

Read more about Lantern Pharma Reports HARMONIC(TM) Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer; Exon 21 L858R NSCLC...

Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer

Read more about Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer

DALLAS--(BUSINESS WIRE)--Jun 2, 2026-- Lantern Pharma Inc. (NASDAQ: LTRN), an AI-driven precision oncology company, today reported clinical data and updates in the form of a presentation from its ongoing Phase 2 HARMONIC™ trial (NCT05456256) evaluating LP-300 in combination with carboplatin...

Predicting response to immunochemotherapy in EGFR-mutant lung adenocarcinoma after third-generation TKI resistance using CT radiomics-based habitat imaging

Read more about Predicting response to immunochemotherapy in EGFR-mutant lung adenocarcinoma after third-generation TKI resistance using CT radiomics-based habitat imaging

BackgroundThird-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) resistance poses a significant therapeutic challenge in ad Introduction Lung adenocarcinoma driven by EGFR mutations is commonly treated with third-generation TKIs, yet acquired resistance remains a major clinical challenge (1–3). Following...

Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer

Read more about Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer

Harmonic Presentation in form of 8K DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an AI-driven precision oncology company, today reported clinical data and updates in the form of a presentation from its ongoing Phase 2 HARMONIC™ trial (NCT05456256) evaluating LP-300 in...

Role of VEGFA/VEGFR2 signaling in predicting clinical outcomes of EGFR-TKI treatment in EGFR-mutant non-small cell lung cancer

Read more about Role of VEGFA/VEGFR2 signaling in predicting clinical outcomes of EGFR-TKI treatment in EGFR-mutant non-small cell lung cancer

Background Dual inhibition of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) pathways may improve outcomes in metastatic EGFR-mutant NSCLC, but VEGF inhibitors are not universally effective. We evaluated the impact of VEGFA and VEGFR2 expressions on...

National Kidney Foundation and U.S. Pharmacy Organizations Call for Transition to Race-Free eGFR in Medication Decision-Making

Read more about National Kidney Foundation and U.S. Pharmacy Organizations Call for Transition to Race-Free eGFR in Medication Decision-Making

New York, NY - June 1, 2026 - A coalition of leading U.S. pharmacy organizations, in collaboration with the National Kidney Foundation (NKF), is urging a nationwide transition to race-free estimated glomerular filtration rate (eGFR), adjusted for body surface area,...

First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations

Read more about First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations

Abstract Background: Sunvozertinib received accelerated approval for use in later lines of therapy for patients with advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations. Data are needed on the efficacy and safety of...

Subscribe to Newsfeed